Comparative efficacy of nebivolol versus carvedilol on left ventricular function and exercise capacity in patients with nonischemic dilated cardiomyopathy. A 12-month study

American Heart Journal

Volumn 150, Issue 5, 2005, Pages 985.e9-985.e18

  Patrianakos, Alexandros P ^a   Parthenakis, Fragiskos I ^a   Mavrakis, Hercules E ^a   Diakakis, George F ^a   Chlouverakis, Gregorios I ^a   Vardas, Panos E ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CARVEDILOL; NEBIVOLOL;

ADULT; AGED; ARTICLE; BRADYCARDIA; CLINICAL TRIAL; COMPARATIVE STUDY; CONGESTIVE CARDIOMYOPATHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLE; DISEASE CLASSIFICATION; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPNEA; ECHOCARDIOGRAPHY; EXERCISE; EXERCISE TEST; FEMALE; FOLLOW UP; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; NONISCHEMIC DILATED CARDIOMYOPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; TREATMENT OUTCOME;

EID: 27744437930     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2005.07.024     Document Type: Article

References (44)

1. J.A. Thomas, and B.H. Marks Plasma norepinephrine in congestive heart failure Am J Cardiol 41 1978 233 243
2. J.N. Cohn, T.B. Levine, and M.T. Olivari Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure N Engl J Med 311 1984 819 823
3. M. Packer, M.R. Bristow, and J.N. Cohn Effect of carvedilol on morbidity and mortality in chronic heart failure N Engl J Med 334 1996 1349 1355
4. CIBIS-II Investigators and Committees The Cardiac Insufficiency Bisoprolol Study-II (CIBIS-II): a randomised trial Lancet 353 1999 9 13
5. MERIT-HF Study Group Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet 353 1999 2001 2007
6. M.J. Domanski, and BEST Investigators beta-Blocker Evaluation of Survival Trial (BEST) J Am Coll Cardiol 35 2000 202A 203A
7. Xamoterol in Severe Heart Failure Study Group Xamoterol in severe heart failure Lancet 336 1990 1 6
8. P.A. Poole-Wilson, K. Swedberg, J.G.F. Cleland for the COMET investigators Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial Lancet 362 2003 7 13
9. J.R. Cockroft, P.H.J. Chowenczyk, and S.E. Brett Nebivolol vasodilates human forearm vasculature: evidence for l-arginine NO-dependent mechanism J Pharmacol Exp Ther 274 1995 1067 1071
10. L. Kalinowski, L. Dobrucki, and M. Szczepanska-Konkel Third-generation [beta]-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action Circulation 107 2003 2747 2752
11. D.M. Flather, C.M. Shibata, and J.A. Coats Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS) Eur Heart J 26 2005 215 225
12. N.B. Schiller, P.M. Shah, and M. Crawford Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-dimensional Echocardiograms J Am Soc Echocardiogr 2 1989 358 367
13. J.G. Dumesnil, G. Gaudreault, and G.N. Honos Use of Valsalva maneuver to unmask left ventricular diastolic function abnormalities by Doppler echocardiography in patients with coronary artery disease or systemic hypertension Am J Cardiol 68 1991 515 519
14. M. Packer, A. Coats, M. Fowler for the Carvedilol Prospective Randomized Cumulative Survival Study Group Effect of carvedilol on survival in severe chronic heart failure N Engl J Med 334 2001 1651 1658
15. H.J. Dargie, and The CAPRICORN Investigators Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomized trial Lancet 357 2001 1385 1390
16. R.M. Bristow, M.A. Feldman, and F.A. Kirkwood Selective versus nonselective β-blockade for heart failure therapy: are there lessons to be learned from the COMET trial? J Card Fail 9 2003 444 453
17. M. Metra, R. Giubbini, and S. Nodari Differential effects of β-blockers in patients with heart failure a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol Circulation 102 2000 546 551
18. M. Packer, G.V. Antonopoulos, and J.A. Berlin Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis Am Heart J 141 2001 899
19. S.D. Katz, L. Biasucci, and C. Sabba Impaired endothelium-mediated vasodilation in the peripheral vasculature of patients with congestive heart failure J Am Coll Cardiol 19 1992 918 925
20. M. Broeders, P. Doevendans, and B. Bekkers Nebivolol: a third generation-blocker that augments vascular nitric oxide release Circulation 102 2000 877 884
21. M.R. Bristow beta-Adrenergic receptor blockade in chronic heart failure Circulation 101 2000 558 569
22. M. Packer beta-Adrenergic blockade in chronic heart failure: principles, progress, and practice Prog Cardiovasc Dis 41 1998 39 52
23. M.R. Bristow, R. Ginsburg, and V. Umans beta-1 and beta-2 Adrenergic-receptors subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta-1 receptor down-regulation in heart failure Circ Res 59 1986 297 309
24. 1-Adrenergic receptors in the nonfailing and failing human heart J Pharmacol Exp Ther 247 1988 1039 1045
25. F.I. Parthenakis, E.M. Kanoupakis, and G.E. Kochiadakis Left ventricular diastolic filling pattern predicts cardiopulmonary determinants of functional capacity in patients with congestive heart failure Am Heart J 140 2000 338 344
26. M.R. Barbara, S.W. Gerald, and M. Ferrari Comparison of left ventricular systolic and diastolic function in patients with idiopathic dilated cardiomyopathy and mild heart failure versus those with severe heart failure Am J Cardiol 90 2002 390 394
27. N. Smart, B. Haluska, and R. Leano Determinants of functional capacity in patients with chronic heart failure: role of filling pressure and systolic and diastolic function Am Heart J 149 2005 152 158
28. B. Andersson, K. Caidahl, and A. di Lenarda Changes in early and late diastolic filling patterns induced by long-term adrenergic beta-blockade in patients with idiopathic dilated cardiomyopathy Circulation 94 1996 673 682
29. B. Andersson, S.O. Stromblad, and M. Lomsky Heart rate dependency of cardiac performance in heart failure patients treated with metoprolol Eur Heart J 20 1999 575 583
30. R. Quaife, E. Gilbert, and P. Christian Effects of carvedilol on systolic and diastolic left ventricular performance in idiopathic dilated cardiomyopathy or ischemic cardiomyopathy Am J Cardiol 78 1996 779 784
31. I. Clements, and W. Miller Effect of metoprolol on rest and exercise left ventricular systolic and diastolic function in idiopathic dilated cardiomyopathy Am Heart J 141 2001 259 266
32. S. Capomolla, O. Febo, and M. Gnemmi β-Blockade therapy in chronic heart failure: diastolic function and mitral regurgitation improvement by carvedilol Am Heart J 139 2000 596 608
33. W.J. Paulus, P.J. Vantrimpont, and A.M. Shah Acute effects of nitric oxide on left ventricular relaxation and diastolic distensibility in humans Circulation 89 1994 2070 2078
34. 2- adrenergic receptors hastens relaxation and mediates phosphorylation of phospholamban, I. Troponin, and C-protein in ventricular myocardium from patients with terminal heart failure Circulation 99 1999 65 72
35. S. Engelhardt, L. Hein, and V. Dyachenkow Altered calcium handling is critically involved in the cardiotoxic effects of chronic β-adrenergic stimulation Circulation 109 2004 1154 1160
36. 1-Adrenergic stimulation is coupled to cardiac myocyte hypertrophy Am J Physiol 260 1991 H953 H956
37. S. Reiken, X.H. Wehrens, and J.A. Vest beta-Blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure Circulation 107 2003 2395 2397
38. T.A. Koshimizu, G. Tsujimoto, and A. Hirasawa Carvedilol selectively inhibits oscillatory intracellular calcium changes evoked by human alpha1D- and alpha1B-adrenergic receptors Cardiovasc Res 63 2004 662 672
39. 2-adrenoceptor agonists Am Heart J 142 2001 e11
40. Book WM. Carvedilol: a nonselective beta blocking agent with antioxidant properties. Congest Heart Fail 2002;8:173-177, 190.
41. Y. Nishiyama, H. Ikeda, and N. Haramaki Oxidative stress is related to exercise intolerance in patients with heart failure Am Heart J 135 1998 115
42. K. Nakamura, K. Kusano, and Y. Nakamura Carvedilol decreases elevated oxidative stress in human failing myocardium Circulation 105 2002 2867 2871
43. M.A. Hlatky, R.E. Boineau, and M.B. Higginbotham A brief self-administered questionnaire to determine function capacity (The Duke Activity Status Index) Am J Cardiol 64 1989 651 654
44. R.K. Oka, N.A. Stotts, and M.W. Dae Daily physical activity levels in congestive heart failure Am J Cardiol 71 1993 921 925